Threshold’s Glufosfamide Misses Endpoint In Phase III For Refractory Pancreatic Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Final results from separate Phase II first-line pancreatic cancer trial with Lilly’s Gemzar due in third quarter; company had reported “encouraging” top-line data in December.